Text Size:

FDA Fast-Tracks Licensure of MF59 Adjuvanted Influenza Vaccine

Posted: 9/16/2015 9:33:17 AM | with 2 comments


During the Sept. 15, 2015 meeting of the FDA's advisory committee on vaccines, Vaccines and Related Biological Products Advisory Committee (VRBPAC), the committee voted to fast-track licensure of the MF59 adjuvanted Fluad influenza vaccine. NVIC's President and Co-Founder, Barbara Loe Fisher gave the following public comment in opposition to licensure of the Fluad vaccine. NVIC has also issued a press release on the VRBPAC decision that may be read here.
 

Public Comment
Barbara Loe Fisher, Co-founder and President
 National Vaccine Information Center
Opposition to Fast Track Licensure of MF59 Adjuvanted Fluad
FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC)
Sept. 15, 2015
 
 
Squalene adjuvants hyper-stimulate the immune system and have been linked with development of autoimmunity, narcolepsy and other chronic disease.1 2 3 Based on the very limited safety and immunogenicity evidence submitted by Novartis,4 MF59 adjuvanted Fluad vaccine should not be fast tracked to licensure for use by seniors over age 65 in the U.S. for the following reasons:  
  1. FDA states there is uncertainty about how MF59 affects immune function but it is “thought” to activate local cells and has been “shown to directly increase phagocytosis” in human immune cells and to induce cytokines.5If MF59 does that, it is an active ingredient and should be proven safe in a placebo controlled trial. 
  2. Influenza vaccines induce immune mediated responses, whether adjuvanted or unadjuvanted. Comparing adverse responses following receipt of one adjuvanted bioactive product to those of an unadjuvanted bioactive product does not prove safety unless both are compared to an inactive placebo.6 7  Novartis did not compare Fluad to an inactive placebo. 
  3. It is well known that responses to vaccination are affected by genetic factors. The Pivotal Study population clearly was not genetically representative of U.S. seniors over age 65, a population that is over 80 percent Caucasian, 9 percent Black, 7 percent Hispanic and 4 percent Asian.8 Fluad was only given to about 1,000 U.S. seniors, while more than 2,400 Fluad recipients were from countries with high majority Asian or Hispanic populations.9 
  4. The trial exclusion criteria is so broad that the health of most of the study participants does not match that of the majority of U.S. seniors over age 65, of whom two-thirds have two or more chronic conditions such as heart, lung and kidney disease,10 11 and will be candidates for receipt of Fluad post-licensure. 
  5. Compared to Agriflu, Fluad produced a much higher number of pain, tenderness, redness and swelling reports; a higher number of systemic adverse event reports and more deaths and cases of new onset chronic disease.12 
  6. The Pivotal Study provides no information about the safety of giving seniors with multiple chronic conditions repeated doses of squalene adjuvanted Fluad every year and no information about how Fluad performs when given simultaneously with other vaccines. 
  7. Using surrogate markers in the Pivotal Study, Novartis was not able to demonstrate that Fluad was superior to Agriflu with regard to immunogenicity, while Novartis was able to demonstrate that squalene adjuvanted Fluad is more reactive.13
Why does Fluad need to be fast tracked to licensure for seniors without additional evidence? There is public concern that fast tracking Fluad is really about fast tracking MF59 to licensure so it can be added to lots of new vaccines targeting infants, pregnant women and every American without adequate evidence for safety or effectiveness.
  
References:

1 Kuroda Y, Nacionales DC et al. Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine. Biomed Pharmacother 2004; 58(5): 325-327.
 
4 Novartis. FDA Advisory Committee Briefing Document: Fluad, Seasonal Adjuvanted Trivalent Influenza Vaccine (aTIV). FDA Vaccines and Related Biological Products Advisory Committee Meeting Sept. 15, 2015.
 
5 FDA. Briefing Document: Influenza Vaccine, Adjuvanted Fluad, Novartis Vaccines and Diagnostics, Inc, Applicant. Vaccines and Related Biological Products Advisory Committee Sept. 15, 2015 Meeting. Page. 6.
 
6 Drugs.com. What is a placebo? Feb. 10, 2013.
 
7  Massachusetts General Hospital. Clinical Trials 101: Placebo Controlled Trials.
 
8 Ortman JM, Velkoff VA, Hogan H. An Aging Nation: The Older Population in the United States. US Census Bureau May 2014. Table 3, page 12.
 
9 FDA. Briefing Document: Influenza Vaccine, Adjuvanted Fluad, Novartis Vaccines and Diagnostics, Inc, Applicant. Vaccines and Related Biological Products Advisory Committee Sept. 15, 2015 Meeting. Table 3, page 11.
 
11 Novartis. . FDA Advisory Committee Briefing Document: Fluad, Seasonal Adjuvanted Trivalent Influenza Vaccine (aTIV). FDA Vaccines and Related Biological Products Advisory Committee Meeting Sept. 15, 2015. Table 29, page 62.
 
12 FDA. Briefing Document: Influenza Vaccine, Adjuvanted Fluad, Novartis Vaccines and Diagnostics, Inc, Applicant. Vaccines and Related Biological Products Advisory Committee Sept. 15, 2015 Meeting. Tables 9 & 10, pages 17 and 18.
 
13 FDA. Briefing Document: Influenza Vaccine, Adjuvanted Fluad, Novartis Vaccines and Diagnostics, Inc, Applicant. Vaccines and Related Biological Products Advisory Committee Sept. 15, 2015 Meeting. Page 5.
 


Posted: 9/16/2015 9:33:17 AM | with 2 comments


Comments
z

Make a Difference Support NVIC

NVIC is 100% funded by donations. Please give.
Help educate families about preventing vaccine injury and death by donating to NVIC today.

Discover How You Can Take Action to Support Our Efforts

Support NVIC!

Newsletter Topic Archives

www.businesswire.com/news/home/20150916006343/en/National-Vaccine-Information-Center-Questions-FDA-Fast#.VfrlNHu-XNA
July 2017(4)
June 2017(5)
May 2017(3)
April 2017(2)
February 2017(5)
November 2016(2)
October 2016(1)
September 2016(1)
June 2016(1)
April 2016(2)
March 2016(1)
February 2016(1)
January 2016(3)
December 2015(2)
November 2015(2)
October 2015(1)
September 2015(3)
August 2015(2)
July 2015(3)
June 2015(2)
May 2015(1)
April 2015(3)
March 2015(2)
January 2015(3)
December 2014(2)
November 2014(2)
October 2014(2)
September 2014(1)
August 2014(2)
May 2014(2)
April 2014(2)
February 2014(3)
January 2014(1)
December 2013(2)
November 2013(3)
October 2013(1)
September 2013(2)
August 2013(4)
July 2013(2)
June 2013(2)
May 2013(2)
April 2013(3)
March 2013(4)
February 2013(2)
January 2013(3)
December 2012(1)
November 2012(1)
October 2012(3)
September 2012(3)
August 2012(2)
July 2012(2)
June 2012(1)
May 2012(2)
March 2012(2)
February 2012(2)
January 2012(3)
December 2011(3)
November 2011(1)
October 2011(4)
September 2011(1)
August 2011(1)
July 2011(2)
June 2011(4)
May 2011(1)
April 2011(1)
March 2011(4)
February 2011(5)
January 2011(1)
December 2010(1)
November 2010(2)
September 2010(2)
August 2010(4)
July 2010(1)
June 2010(2)
May 2010(4)
April 2010(4)
March 2010(2)
February 2010(2)
January 2010(3)
October 2009(1)
September 2009(2)
August 2009(2)
July 2009(2)
June 2009(3)
May 2009(2)
March 2009(3)
February 2009(2)
January 2009(2)
December 2008(3)
April 2008(1)
September 2005(1)
March 2004(1)
August 2000(4)
May 1997(1)

Connect with us!

  • NVIC Pinterest
  • NVIC Facebook
  • NVIC Twitter
  • NVIC Youtube
  • NVIC Instagram

Ask 8 Kiosk & Educational Marketplace

Ask 8 Questions

Visit our Ask 8 Kiosk to explore a variety of FREE educational materials, from posters and brochures to embeddable web graphics and other resources.

View FREE Downloads